Our mission is to shape the future of medicine by providing powerful reagents for research and diagnostics, and by developing safe and efficacious medicines.
At Avacta we have developed Affimer® technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets.
Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.
Avacta Life Sciences offer custom affinity reagents for reagents, diagnostic and therapeutic use. The reagents are called Affimers and are derived from a small human scaffold. The have two binding loops and are selected from multiple large libraries using phage display. Binders are normally nM and specificity is excellent, down to single amino acids in some cases. We can tailor characterization and validation to suit customer requirements and a standard project takes 10 - 12 weeks.
Avacta Life Sciences has not received any reviews.
Avacta Life Sciences has not received any endorsements.